All In Biotech

NDA 209863 · Antares Pharma INC

Xyosted (Autoinjector)

Testosterone Enanthate · Subcutaneous

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 28, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

47

9 Phase 3, 5 recruiting

FAERS reports

1,642

475 serious, 27 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2025.

XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established. Safety and efficacy of XYOSTED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established ( 1 ). Safety and efficacy of XYOSTED in males less than 18 years old have not been established ( 1 , 8.4 ).

Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone,...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • XYOSTED (AUTOINJECTOR) · TESTOSTERONE ENANTHATE 100MG/0.5ML (100MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • XYOSTED (AUTOINJECTOR) · TESTOSTERONE ENANTHATE 50MG/0.5ML (50MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • XYOSTED (AUTOINJECTOR) · TESTOSTERONE ENANTHATE 75MG/0.5ML (75MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone Enanthate" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue354
  • injection site pain160
  • injection site haemorrhage142
  • drug ineffective111
  • off label use100
  • injection site mass61
  • fatigue57
  • injection site bruising56
  • accidental exposure to product53
  • product dose omission52
  • product use in unapproved indication51
  • injection site erythema41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20056
20065
20077
200810
200917
201010
20116
201215
201316
201425
201555
201639
201726
201831
201980
2020198
2021205
2022212
2023240
202453
2025242
2026142

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 196 on PubMed

Sponsor: Antares Pharma INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.